Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of OTS167PO in Advanced Breast Cancer and Triple Negative Breast Cancer
jRCT2031230090Phase 1Completed
- Sponsor
- OncoTherapy Science, Inc.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of OTS167 in breast cancer (2 cohorts), sponsored by OncoTherapy Science, Inc. Primary endpoint: Maximum tolerated dose of OTS167PO. Started Mar 2021; status: completed.
02
Drugs
OTS167
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031230090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230090.